Oligodendroglioma Clinical Trials

Find Oligodendroglioma Clinical Trials Near You

A Multi-Centered Evaluation of Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma (HGG): An Approach to Drug Screening That Requires Confirmation

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Better treatments are needed for high-grade gliomas (HGG), and new ways of treating this disease should be tested. The investigators want to see if giving medicine before radiation works well. After radiation, MRI scans can be harder to understand because radiation changes how the brain looks on the scan. If new medicines are given before radiation, the scans are easier to read. First, the investigators need to find out if giving chemotherapy early works using a drug we already know can treat gliomas. The investigators will start with temozolomide, which is the only chemotherapy approved by the FDA for HGG. If this approach is successful, the investigators can then test new drugs using this screening method.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Pathologic diagnosis of high-grade glioma

• Residual measurable post-operative contrast enhancing tumor

• Lack of urgency in requiring immediate radiation or chemotherapy (mass effect, mid-line shift, herniation, etc.)

• Ability to provide informed consent

• Willingness to comply with all study procedures and availability for the duration of the study

• Male or female, aged 18-80.

• Karnofsky Performance Status ³70%.

• Patients must have the following organ and marrow functions:

• Absolute neutrophil count ≥1,500/µL Platelets ≥100,000/µL Hemoglobin ≥ 9 g/dL Total bilirubin £ 1.5 × institutional upper limit of normal (ULN), (except for patients with known Gilbert's syndrome who must have normal direct bilirubin) AST (SGOT)/ALT (SGPT) £ 2.5 × ULN Creatinine £ 1.5 × ULN OR Creatinine clearance ≥ 60 mL/min/1.73m2 APTT/PTT ≤ 1.5 × ULN Sodium ≥ the institutional lower limit of normal

• Ability to take oral medication and be willing to adhere to the pre-radiation temozolomide regimen

⁃ For females of reproductive potential: use of highly effective contraception for at least 1 week prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of pr-radiation temozolomide administration

⁃ For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner

⁃ Patients must have measurable disease as defined by RANO criteria.

Locations
United States
New Jersey
Cooper University HealthCare
RECRUITING
Camden
Time Frame
Start Date: 2026-07-13
Estimated Completion Date: 2029-09
Participants
Target number of participants: 70
Treatments
Experimental: All Patients
Sponsors
Collaborators: Musella Foundation, Virginia Commonwealth University, Georgetown University, University of Virginia, Imaging Biometrics, LLC, Wake Forest University, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, West Virginia University
Leads: The Cooper Health System

This content was sourced from clinicaltrials.gov